THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Meilleure Health International Industry Group Limited, you should at once hand this circular and the accompanying form of proxy to the purchaser or the transferee or to the bank, licensed securities dealer or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

美瑞健康国际产业集团
Meilleure Health International Industry Group

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED
美瑞健康國際產業集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 2327)

GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; RE-ELECTION OF DIRECTORS; PROPOSED PAYMENT OF FINAL DIVIDEND; CLOSURE OF REGISTER OF MEMBERS; AND NOTICE OF ANNUAL GENERAL MEETING

A notice convening the AGM to be held at Portion 2, 12/F, The Center, 99 Queen's Road Central, Central, Hong Kong on Friday, 26 June 2026 at 11:00 a.m. is set out on pages 16 to 20 of this circular. A form of proxy for use by the Shareholders at the AGM is enclosed. Whether or not you intend to attend and vote at the AGM in person, please complete the form of proxy in accordance with the instructions set out therein and return it to the Company's Hong Kong branch share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event not later than 48 hours before the time appointed for holding the AGM or any adjourned meeting (as the case may be). Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjourned meeting (as the case may be) should you so wish. For the avoidance of doubt, holders of Treasury Shares, if any, shall abstain from voting at the Company's general meeting.

28 April 2026

CONTENTS

Page

Definitions 1

Letter from the Board

Introduction 4

Repurchase Mandate 5

General Mandate 5

Re-election of Directors 6

Proposed payment of Final Dividend 6

Annual General Meeting 6

Voting at the Annual General Meeting 6

Closure of Register of Members 7

Responsibility Statement 7

Additional Information 7

Recommendation 7

Appendix I – Explanatory Statement of the Repurchase Mandate 8

Appendix II – Details of the Re-elected Directors 12

Notice of Annual General Meeting 16

In this circular, the following expressions shall have the following meanings unless the context indicates otherwise:

"2019 Share Option Scheme"	the share option scheme adopted by the Company on 20 June 2019 and became effective on 28 June 2019
"AGM"	the annual general meeting of the Company to be held at Portion 2, 12/F, The Center, 99 Queen's Road Central, Central, Hong Kong on Friday, 26 June 2026 at 11: 00 a.m. for the purposes of considering the businesses set out in the AGM Notice and, if thought fit, passing the resolutions set out therein, or any adjourned meeting (as the case may be)
"AGM Notice"	the notice for convening the AGM as set out on pages 16 to 20 in this circular
"Board"	the board of Directors
"Bye-laws"	the bye-laws of the Company
"CCASS"	the Central Clearing and Settlement System established and operated by HKSCC
"CG Code"	the Corporate Governance Code, as set out in Appendix C1 to the Listing Rules
"Company"	Meilleure Health International Industry Group Limited, an exempted company incorporated in Bermuda with limited liability and the Shares of which are listed on the main board of the Stock Exchange
"Director(s)"	the director(s) of the Company
"Final Dividend"	the proposed final dividend of HK0.4 cents per Share for the year ended 31 December 2025 to the Shareholders whose names appear on the Register of Members on the Record Date
"General Mandate"	the general mandate to allot, issue and deal with new Shares (including a sale or transfer of Treasury Shares out of treasury, if any) of not exceeding 20% of the total number of Shares in issue (excluding Treasury Shares, if any) as at the date of passing of the ordinary resolution in relation thereof

"Group"	the Company and its subsidiaries
"HK$"	Hong Kong dollar, the lawful currency of Hong Kong
"HKSCC"	Hong Kong Securities Clearing Company Limited
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Latest Practicable Date"	17 April 2026, being the latest practicable date for ascertaining certain information contained in this circular prior to its publication
"Listing Rules"	The Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited as amended, supplemented or otherwise modified from time to time
"PRC"	the People's Republic of China, and for the purpose of this circular, excludes Hong Kong, the Macau Special Administrative Region and Taiwan region
"Record Date"	Wednesday, 5 August 2026, being the record date for determining entitlements of the Shareholders to the Final Dividend
"Register of Members"	the principal or branch register of members of the Company maintained in Bermuda or Hong Kong, respectively
"Repurchase Mandate"	the authority to repurchase fully paid up Shares of up to 10% of the total number of Shares in issue (excluding Treasury Shares, if any) as at the date of passing of the ordinary resolution in relation thereof
"SFC"	the Securities and Futures Commission in Hong Kong
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) as amended, supplemented or otherwise modified from time to time
"Share(s)"	the ordinary share(s) of HK$0.01 each in the share capital of the Company
"Shareholder(s)"	the holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited

"Takeovers Code"	The Codes on Takeovers and Mergers as amended, supplemented or otherwise modified from time to time
"Treasury Shares"	has the meaning ascribed to it under the Listing Rules
"%"	per cent

美瑞健康国际产业集团
Meilleure Health International Industry Group

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED
美瑞健康國際產業集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 2327)

Executive Directors:
Mr. Zhou Xuzhou *(Co-Chairman)*
Dr. Zeng Wentao *(Co-Chairman)*
Ms. Zhou Wen Chuan
(Vice Chairman and Chief Executive Officer)

Non-Executive Director:
Dr. Mao Zhenhua

Independent Non-Executive Directors:
Professor Chau Chi Wai, Wilton
Mr. Chen Shi
Mr. Wu Peng

Registered office:
Clarendon House
2 Church Street
Hamilton HM 11
Bermuda

Head office and principal place of business in Hong Kong:
Unit 2906
Tower 1, Lippo Centre
89 Queensway
Admiralty
Hong Kong

28 April 2026

To the Shareholders

Dear Sir/Madam,

GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; RE-ELECTION OF DIRECTORS; PROPOSED PAYMENT OF FINAL DIVIDEND; CLOSURE OF REGISTER OF MEMBERS; AND NOTICE OF ANNUAL GENERAL MEETING

INTRODUCTION

The purpose of this circular is to provide you with information relating to the resolutions to be proposed at the AGM regarding (i) the granting of the Repurchase Mandate to the Directors; (ii) the granting of the General Mandate to the Directors; (iii) the re-election of Directors; and (iv) the proposed payment of the Final Dividend.

REPURCHASE MANDATE

At the AGM, an ordinary resolution will be proposed to grant the Repurchase Mandate to the Directors. The authority to be given under the Repurchase Mandate is restricted to the repurchase of Shares on the Stock Exchange in accordance with the Listing Rules.

In accordance with the Listing Rules, an explanatory statement of the Repurchase Mandate is set out in Appendix I of this circular in order to provide you with requisite information reasonably necessary to enable you to make an informed decision on whether to vote for or against the ordinary resolution to be proposed at the AGM for granting the Repurchase Mandate to the Directors.

The full text of the resolution in respect of the Repurchase Mandate is set out in resolution no. 5 in the AGM Notice. As at the Latest Practicable Date, there were 4,088,428,636 Shares in issue (excluding Treasury Shares, if any) and assuming that no new shares are allotted or issued prior to the AGM, the total number of Shares that may be repurchased under the Repurchase Mandate will be 408,842,863 Shares, calculated based on 10% of the total number of shares of the Company in issue (excluding Treasury Shares, if any) as at the date of passing of the ordinary resolution in relation thereto.

GENERAL MANDATE

At the AGM, an ordinary resolution will also be proposed to grant the General Mandate to the Directors. The general mandate granted to the Directors at the last annual general meeting of the Company held on 27 June 2025 will lapse at the conclusion of the AGM. The General Mandate will give the Directors the flexibility and discretion to issue new Shares. In addition, an ordinary resolution will be proposed to extend the General Mandate by adding to it the number of such Shares repurchased under the Repurchase Mandate.

The full texts of the resolutions in respect of the General Mandate and the extension of the General Mandate are set out in resolutions nos. 6 and 7 in the AGM Notice, respectively.

As at the Latest Practicable Date, there were 4,088,428,636 Shares in issue (excluding Treasury Shares, if any) and assuming that no new shares are allotted or issued prior to the AGM, the total number of Shares that may be issued under the General Mandate will be 817,685,727 Shares, calculated based on 20% of the total number of shares of the Company in issue (excluding Treasury Shares, if any) as at the date of passing of the ordinary resolution in relation thereto.

RE-ELECTION OF DIRECTORS

Pursuant to the Bye-laws and in accordance with Code Provision B.2.2 of the CG Code, Ms. Zhou Wen Chuan, Dr. Zeng Wentao and Mr. Wu Peng will retire and, being eligible, will offer themselves for re-election at the AGM. Information on the retiring Directors is set out in Appendix II to this circular.

PROPOSED PAYMENT OF FINAL DIVIDEND

Subject to the approval of Shareholders at the AGM, the Board proposed to pay a final dividend of HK0.4 cents per Share for the year ended 31 December 2025 to the Shareholders whose names appear on the Register of Members as at the close of business on Wednesday, 5 August 2026. The proposed Final Dividends are expected to be paid in Hong Kong dollars on or before Friday, 28 August 2026.

In order to determine the entitlement of the shareholders to receive the proposed Final Dividend, if approved, the register of members of the Company will be closed from Tuesday, 4 August 2026 to Wednesday, 5 August 2026, during which no transfer of the Shares will be registered.

ANNUAL GENERAL MEETING

A notice convening the AGM is set out on pages 16 to 20 of this circular and a form of proxy for use by Shareholders at the AGM is enclosed with this circular. Whether or not you intend to attend and vote at the AGM in person, you are requested to complete the form of proxy in accordance with the instructions set out therein and return it to the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event, not less than 48 hours before the time appointed for holding the AGM or any adjourned meeting (as the case may be). Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjourned meeting (as the case may be) should you so wish.

VOTING AT THE ANNUAL GENERAL MEETING

Pursuant to the Rule 13.39 of the Listing Rules, all votes of Shareholders at a general meeting must be taken by poll. The chairman of the meeting will therefore demand a poll for every resolution put to the vote at the AGM pursuant to bye-law 66 of the Bye-laws. Separately, holders of Treasury Shares (if any) shall abstain from voting on matters that require shareholders' approval at the Annual General Meeting.

CLOSURE OF REGISTER OF MEMBERS

The Register of Members for the AGM will be closed from Monday, 22 June 2026 to Friday, 26 June 2026, both days inclusive, during which period no transfer of shares will be registered. In order to qualify for attendance at the AGM to be held on Friday, 26 June 2026, all transfers accompanied by the relevant share certificates must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, for registration not later than 4: 30 p.m. on Thursday, 18 June 2026. The record date for the purpose of ascertaining Shareholders' right to attend and vote at the AGM will be 26 June 2026.

RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

ADDITIONAL INFORMATION

Your attention is drawn to the additional information set out in Appendix I (Explanatory Statement on the Repurchase Mandate) and Appendix II (Details of the Re-elected Directors) to this circular.

RECOMMENDATION

The Directors are of the opinion that the resolutions to be proposed at the AGM as referred in this circular are in the interests of the Company and the Shareholders and recommend the Shareholders to vote in favour of the resolutions to be proposed at the AGM.

Yours faithfully,
For and on behalf of
Meilleure Health International Industry Group Limited
Zhou Wen Chuan
Executive Director and Chief Executive Officer

This Appendix serves as an explanatory statement required by Rule 10.06(1)(b) of the Listing Rules to provide you with all the information reasonably necessary to enable you to make an informed decision on whether to vote for or against the ordinary resolution to be proposed at the AGM for granting the Repurchase Mandate to the Directors.

SHAREHOLDERS' APPROVAL

All proposed repurchases of Shares on the Stock Exchange by a company with its primary listing on the Stock Exchange must be approved in advance by an ordinary resolution, either by way of a general mandate or by specific approval.

REASONS FOR SHARE REPURCHASE

The Directors believe that it is in the interests of the Company and Shareholders for the Directors to continue to have general authority from the Shareholders to enable the Company to repurchase Shares on the Stock Exchange. Such repurchases may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share. Shareholders are assured that such repurchases of Shares will only be made when the Directors believe that they are appropriate and will benefit the Company and Shareholders as a whole.

SHARE CAPITAL

As at the Latest Practicable Date, the Company had 4,088,428,636 Shares in issue (excluding 5,328,000 Treasury Shares).

Subject to the passing of the proposed ordinary resolution approving to grant the Repurchase Mandate to the Directors and on the assumptions that no new Shares are allotted or issued, and no existing Shares are repurchased by the Company prior to the AGM, the exercise of the Repurchase Mandate in full would enable the Company to repurchase a maximum of 408,842,863 Shares, representing 10% of the Shares in issue (excluding Treasury Shares, if any) as at the Latest Practicable Date.

FUNDING OF SHARE REPURCHASE

Any repurchases must be funded out of funds legally available for such purpose in accordance with the Company's memorandum of association and Bye-laws and the laws of Bermuda. Bermuda laws provide that the amount of capital repaid related to a share repurchase may only be paid out of either the capital paid up on the relevant shares, or the funds that would otherwise be available for distribution or dividend or the proceeds of a fresh issue of shares made for the purpose.

Subject to the compliance with the Listing Rules and all applicable laws and regulations, the Company may cancel any shares it repurchased and/or hold such shares as treasury shares for subsequent re-issue or sale subject to consideration of factors including market conditions and the Group's capital management needs at the relevant time of the repurchases.

The exercise of the Repurchase Mandate in full might have a material adverse impact on the working capital and/or gearing level of the Company as compared with the position disclosed in the Company's annual report for the year ended 31 December 2025. However, the Directors do not intend to exercise the Repurchase Mandate to such extent as would, in the circumstances, have a material adverse impact on the working capital and/or gearing level of the Company unless the Directors consider that such purchases are in the interests of the Company.

DISCLOSURE OF INTERESTS

None of the Directors or, to the best of their knowledge having made all reasonable enquiries, any of their respective close associates (as defined in the Listing Rules) has any present intention, in the event that the Repurchase Mandate is approved by Shareholders, to sell any Share to the Company.

No core connected person (as defined in the Listing Rules) has notified the Company that he/she has a present intention to sell any Share to the Company or has undertaken not to sell any of the Shares held by him/her to the Company, in the event that the Repurchase Mandate is approved by Shareholders.

UNDERTAKING OF THE DIRECTORS

The Directors have undertaken to the Stock Exchange that they will exercise the Repurchase Mandate in accordance with the Listing Rules, the regulations set out in the Company's memorandum of association and Bye-laws and the applicable laws of Bermuda.

The Company may cancel such repurchased Shares or hold them as Treasury Shares, subject to market conditions and the Group's capital management needs at the relevant time of the repurchases. For any Treasury Shares deposited with CCASS pending resale on the Stock Exchange, the Company shall (i) procure its broker not to give any instructions to HKSCC to vote at general meetings of the Company for the Treasury Shares deposited with CCASS; and (ii) in the case of dividends or distributions, withdraw the Treasury Shares from CCASS, and either re-register them in its own name as Treasury Shares or cancel them, in each case before the record date for the dividends or distributions, or take any other measures to ensure that it will not exercise any shareholders' rights or receive any entitlements which would otherwise be suspended under the applicable laws if those Shares were registered in its own name as Treasury Shares.

EFFECT OF THE TAKEOVERS CODE AND MINIMUM PUBLIC SHAREHOLDING

If on the exercise of the power to repurchase shares pursuant to the Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purpose of Rule 32 of the Takeovers Code. As a result, a Shareholder or a group of Shareholders acting in concert could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code.

As at the Latest Practicable Date, Mr. Zhou Xuzhou (the "**Controlling Shareholder**") was interested in, beneficially and through controlled corporation, an aggregate of 2,559,928,761 Shares, representing approximately 62.61% of the issued share capital of the Company. If the Directors were to exercise the Repurchase Mandate in full, such Shares would represent approximately 69.57% of the then issued share capital of the Company. The Directors are not aware of any consequences which would arise under the Takeovers Code as a result of any repurchase of Shares pursuant to the Repurchase Mandate.

Pursuant to Rule 8.08 of the Listing Rules, the Company should maintain at least 25% of the issued share capital of the Company be held by the public. Based on the current shareholding of the Controlling Shareholder, if the Directors were to exercise the Repurchase Mandate in full, it would not result in the amount of Shares held by the public being reduced to less than 25%.

SHARE REPURCHASES BY THE COMPANY

During the six months preceding the Latest Practicable Date, the Company has repurchased a total of 7,500,000 Shares on the Stock Exchange, among which, 2,172,000 Shares are held as share repurchased for cancellation but not yet cancelled, 5,328,000 Shares are held as Treasury Shares. Details of the said repurchases of Shares are set out as follows:

Date of repurchase	**Number of Shares repurchased**	**Highest price per Share** *HK$*	**Lowest price per Share** *HK$*
7 January 2026	1,224,000	0.275	0.265
8 January 2026	948,000	0.285	0.275
12 January 2026	3,762,000	0.285	0.265
16 January 2026	1,566,000	0.270	0.265
	7,500,000		

SHARE PRICES

The highest and lowest prices at which the Shares had been traded on the Stock Exchange during each of the previous twelve months preceding the Latest Practicable Date were as follows:

	Price per Share	
	Highest	**Lowest**
	HK$	*HK$*
2025		
April	0.295	0.224
May	0.310	0.290
June	0.310	0.280
July	0.305	0.245
August	0.260	0.236
September	0.290	0.239
October	0.300	0.270
November	0.295	0.270
December	0.295	0.265
2026		
January	0.285	0.245
February	0.270	0.237
March	0.275	0.232
April (Up to the Latest Practicable Date)	0.285	0.248

Set out below are the details of the Directors who retire and, being eligible, will offer themselves for re-election at the AGM pursuant to the Bye-laws:

Ms. Zhou Wen Chuan ("Ms. Zhou"), aged 42, was appointed as an Executive Director on 30 August 2013 and the Chief Executive Officer of the Company on 23 September 2013. She is a member of the nomination committee of the Board.

Ms. Zhou obtained a master's degree in Business Administration from the Chinese University of Hong Kong in 2011. Also, she obtained a master's degree in Science and a dual bachelor's degree in Food Nutrition and Health from the University of British Columbia in 2008 and 2007, respectively. Ms. Zhou is currently a PhD student.

Ms. Zhou is the daughter of Mr. Zhou Xuzhou. Save as disclosed, Ms. Zhou has no relationship with any other directors, senior management or substantial or controlling shareholders of the Company.

Other than holding the directorship in the Company, Ms. Zhou is also the director of Meilleure Hemp International Holdings Limited, Meilleure Group Development Company Limited, Meilleure Enterprise Development Company Limited, Meilleure Property Management and Consultancy Company Limited, U-Home International Enterprises Limited, Meilleure Group Health Service Company Limited, Meilleure Healthcare Company Limited, U-Home Oceania Pty Limited, Australia Hemp Health Pty Ltd, Meilleure Hemp Health Europe SA, Green Gold Health SA, Meilleure Hemp Holding Limited, Meipro Biological Technology Company Limited, Base Affirm International Limited, Shenzhen Jibenfenxi Aestheic Medical Clinic* (深圳肌本分析醫療美容診所), U-Seraphim Company Limited and U-home Solar SA, all of which are subsidiaries of the Company.

Ms. Zhou is the director of Shenzhen Wingor Biotechnology Co., Ltd.* (深圳市茵冠生物科技有限公司), a joint venture of the Company. She is also the director of Beijing Mei Ai Kang Technology Co., Ltd.* (北京美艾康科技有限公司), an associate of the Company.

Save as disclosed above and as far as the Directors are aware, Ms. Zhou does not hold any other position in the Company or any other members of the Group, nor did she hold any directorship in any listed public company in the last three years.

Ms. Zhou has entered into a service contract with the Company for a term of three years commencing from 30 August 2025 to 29 August 2028. She is entitled to an annual remuneration of HK$1,200,000 as determined by the Board, subject to annual review with reference to her duties and responsibilities as well as the prevailing market conditions.

As at the Latest Practicable Date, Ms. Zhou had interest in 44,739,000 Shares, representing 1.09% in the total issued Shares within the meaning of Part XV of the SFO (including her interest in 40,239,000 Shares beneficially owned by her, representing 0.98% in the total issued

* *For identification purposes only*

Shares, as well as her interest in 4,500,000 Shares that fall to be issued upon full exercise of the share options granted to her under the 2019 Share Option Scheme, representing 0.11% in the total issued Shares (excluding Treasury Shares)).

Dr. Zeng Wentao ("Dr. Zeng"), aged 62, was appointed as an independent non-executive Director of the Company on 18 October 2017, and was re-designated as an executive Director of the Company on 27 May 2019 and was appointed as a co-chairman of the Company on 20 June 2019. He is a member of the remuneration committee of the Board and the strategic committee of the Board.

Dr. Zeng graduated from Wuhan University with a doctoral degree in Economics. Dr. Zeng founded Hainan Sanyou Real Estate Company Limited (海南三友房地產有限公司) in Hainan in 1990 and acted as its general manager. In 1995, he founded Wuhan Yinhai Property Company Limited (武漢銀海置業有限公司), which was principally engaged in real estate development and technology investment, and acted as its chief executive officer. He has been the chief executive officer of Zhongjia Capital (Wuhan) Investment Management Company Limited (中珈資本(武漢)投資管理有限公司) since March 2017. He is a part-time professor of Zhongnan University of Economics and Law, a member of Zhongnan University of Economics and Law Educational Development Fund and a standing council member of Dong Fureng Foundation (董輔礽基金會). He was the vice-chairman of the 12th and 13th Federation of Industry and Commerce of Wuhan City (武漢市工商聯) and a member of the 11th and 12th People's Consultative Conference of Wuhan City. Dr. Zeng has been a Counselor of the Healthcare Industry Union of Wuhan University Alumni Entrepreneur Association (武漢大學校友企業家聯誼會健康產業聯盟), an organisation dedicated to the promotion of co-operations in the healthcare industry among entrepreneurs who are alumni of Wuhan University, since July 2017. By taking this position, Dr. Zeng has gained an understanding of the healthcare business and has built good relationships with certain entrepreneurs and market players in the healthcare industry. In 2018, Dr. Zeng was appointed as a researcher in health economics of Dong Fureng Economic & Social Development School of Wuhan University, which demonstrated the recognition of Dr. Zeng's knowledge in health economics by the said organisation and has enabled Dr. Zeng to use his managerial experience to contribute to the research work in the health economics area.

Dr. Zeng has no relationship with any directors, senior management or substantial or controlling shareholders of the Company, and he did not hold any positions with the Company or any other members of the Group. Save as disclosed above, Dr. Zeng Wentao has not held directorship in any listed company in the last three years.

Dr. Zeng has entered into a service contract with the Company for a term of three years commencing on 27 May 2025 and ending on 26 May 2028. He is entitled to an annual remuneration of HK$300,000 as determined by the Board, subject to annual review with reference to his duties and responsibilities as well as the prevailing market conditions.

As at the Latest Practicable Date, Dr. Zeng had interest in 77,500,500 Shares, representing 1.90% in the total issued Shares within the meaning of Part XV of the SFO (including his interest in 75,000,000 Shares beneficially owned by him, representing 1.83% in the total issued Shares, as well as his interest in 2,500,500 Shares that fall to be issued upon full exercise of the share options granted to him under the 2019 Share Option Scheme, representing 0.06% in the total issued Shares (excluding Treasury Shares)).

Dr. Zeng has confirmed to the Company: (i) his independence as regards each of the factors referred to in Rule 3.13 of the Listing Rules; (ii) he has not had or is not having any financial or other interests in the business of the Group or any connection with any of the core connected persons (as defined in the Listing Rules) of the Company; and (iii) there are no other factors which may have affected his independence as at the Latest Practicable Date.

Mr. Wu Peng ("Mr. Wu"), aged 44, was appointed as an independent non-executive Director on 27 May 2019. He is a member of the nomination committee of the Company.

Mr. Wu graduated from Tsinghua University with a bachelor's degree in information systems in July 2004 and a doctoral degree (with supply chain management as a key research area) in January 2010. From September 2005 to January 2010, Mr. Wu worked as a research assistant in the Humanities Key Research Base of the Ministry of Education (教育部人文社科重點研究基地) of the PRC and the Research Centre for Contemporary Management Tsinghua University (清華大學現代管理研究中心), where he participated in the study of pharmaceutical products supply chain management strategies. In this position, Mr. Wu conducted investigations and research on the production and operation processes of a number of large sized pharmaceutical companies in the PRC and gained a good understanding of their supply chain management. From March 2010 to November 2012, Mr. Wu was a lecturer at the school of Business Administration of South China University of Technology and was mainly involved in teaching and researching green supply chain management. During this period, from November 2010 to April 2012, Mr. Wu was also a postdoctoral researcher at The Martin Centre for Architectural and Urban Studies of the University of Cambridge, where he was engaged in low-carbon supply chain and low-carbon urban planning and design research work. Since December 2012, Mr. Wu has been teaching green supply chain management and engaging in the research work in this area in the Business School of Sichuan University, first as an associate professor from December 2012 to September 2017 and subsequently as a professor since September 2017. During a five-year period from 2012 to 2017, Mr. Wu was involved in an industrial chain optimisation consulting project, through which he further gained experience in the supply chain management research area. Mr. Wu has been a Counselor of the Society of Management Science and Engineering of China (中國管理科學與工程學會理事) since October 2018.

Mr. Wu has no relationship with any Director, senior management, substantial or controlling shareholder of the Company, and he did not hold any positions with the Company or any other members of the Group.

Mr. Wu has served as an independent director of LightInTheBox Holding Co., Ltd., an online retail company whose shares are listed on the New York Stock Exchange, since January 2019. Save as disclosed above, Mr. Wu did not hold any directorships of any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Mr. Wu has entered into a letter of appointment with the Company for a term of one year commencing on 20 June 2025 and ending on 19 June 2026. Mr. Wu is entitled to an annual remuneration of HK$120,000 as determined by the Board, subject to annual review with reference to his duties and responsibilities as well as the prevailing market conditions.

As at the Latest Practicable Date, Mr. Wu did not have, directly or indirectly, and was not deemed to have any interests in any shares, underlying shares or debentures (as defined under Part XV of the SFO) of the Company which are required to be disclosed pursuant to Part XV of the SFO.

Mr. Wu has confirmed to the Company: (i) his independence as regards each of the factors referred to in Rule 3.13 of the Listing Rules; (ii) he has not had or is not having any financial or other interests in the business of the Group or any connection with any of the core connected persons (as defined in the Listing Rules) of the Company; and (iii) there are no other factors which may have affected his independence as at the Latest Practicable Date.

There is nothing which needs to be disclosed pursuant to Rule 13.51(2) of the Listing Rules nor is there anything which needs to be brought to the attention of the Shareholders in connection with the above retiring Directors.



美瑞健康国际产业集团
Meilleure Health International Industry Group

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED

美瑞健康國際產業集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 2327)

NOTICE IS HEREBY GIVEN that the annual general meeting of Meilleure Health International Industry Group Limited (the "**Company**") will be held at Portion 2, 12/F, The Center, 99 Queen's Road Central, Central, Hong Kong on 26 June 2026 at 11: 00 a.m. (the "**AGM**") for the following purposes:

AS ORDINARY BUSINESS

1. To receive and consider the audited financial statements and the reports of the directors and auditors of the Company and its subsidiaries for the year ended 31 December 2025.

2. To declare and approve a final dividend of HK0.4 cents per share of the Company in respect of the year ended 31 December 2025.

3. To re-elect retiring directors of the Company and to authorise the board of directors of the Company to fix their remuneration.

4. To re-appoint ZHONGHUI ANDA CPA Limited as the auditor of the Company and to authorise the board of directors of the Company to fix their remuneration.

AS SPECIAL BUSINESS

To consider and, if thought fit, to pass with or without amendments, each of the following resolutions as ordinary resolutions of the Company:

ORDINARY RESOLUTIONS

5. "**THAT**:

(a) subject to paragraph (b) of this resolution, the exercise by the Directors of the Company during the Relevant Period (as defined in paragraph (c) of this resolution) of all the powers of the Company to repurchase shares of HK$0.01 each in the capital of the Company on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") or on any other stock exchange on which the securities of the Company may be listed and recognized by the Securities and Futures Commission of Hong Kong and the Stock Exchange for this purpose, subject to and in accordance with all applicable laws and the requirement of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "**Listing Rules**") or of any other stock exchange as amended from time to time, be and is hereby generally and unconditionally approved;

(b) the aggregate number of shares of the Company (the "**Shares**") to be repurchased during the Relevant Period pursuant to the approval in paragraph (a) of this resolution shall not exceed 10% of the total number of shares of the Company in issue (excluding treasury shares ("**Treasury Shares**", which shall have the meaning ascribed to it under the Listing Rules)) on the date of passing of this resolution; and

(c) for the purposes of this resolution, "**Relevant Period**" means the period from the passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the bye-laws of the Company or any applicable law to be held; or

(iii) the revocation or variation of the authority given under this resolution by ordinary resolution of the shareholders of the Company in general meeting."

6. "**THAT**:

(a) subject to paragraphs (b) and (c) of this resolution, the granting of an unconditional general mandate to the directors of the Company during the Relevant Period (as defined in paragraph (d) of this resolution) to allot, issue and deal with additional Shares (including any sale or transfer of Treasury Shares out of treasury) and to make or grant offers, agreements, options (including warrants, bonds, debentures, notes and other securities which carry rights to subscribe for or are convertible into shares of the Company) which might require the exercise of such power be and is hereby generally and unconditionally approved;

(b) the unconditional general mandate under paragraph (a) of this resolution shall not extend the Relevant Period save the directors of the Company may during the Relevant Period make or grant offers, agreements and options (including warrants, bonds, debentures, notes and other securities which carry rights to subscribe for or are convertible into shares of the Company) during the Relevant Period which would or might require the exercise of such power after the end of the Relevant Period;

(c) the aggregate number of Shares allotted or agreed conditionally or unconditionally to be allotted (including Treasury Shares, if any, sold or transferred or agreed conditionally or unconditionally to be sold or transferred, whether pursuant to options or otherwise) by the directors of the Company pursuant to the general mandate in paragraph (a) of this resolution, otherwise than pursuant to (i) a Rights Issue (as defined in paragraph (d) of this resolution) or (ii) any scrip dividend or similar arrangement providing for the allotment of shares in lieu of the whole or part of a dividend on shares of the Company in accordance with the bye-laws of the Company or (iii) any share option scheme of the Company or (iv) the exercise of any rights of subscription or conversion under any existing warrants, bonds, debentures, notes and other securities issued by the Company which carry rights to subscribe for or are convertible into shares of the Company, shall not exceed 20% of the total number of shares of the Company in issue (excluding Treasury Shares, if any) on the date of passing of this resolution; and

(d) for the purposes of this resolution, "**Relevant Period**" means the period from the passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the bye-laws of the Company or any applicable law to be held; or

(iii) the revocation or variation of the authority given under this resolution by ordinary resolution of the shareholders of the Company in general meeting; and

"**Rights Issue**" means an offer of shares in the Company, open for a period fixed by the directors to the holders of shares, whose names appear on the register of members of the Company on a fixed record date in proportion to their then holdings of such shares as at that date (subject to such exclusions or other arrangements as the directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of, or the requirements of any recognised regulatory body or any stock exchange in, any territory applicable to the Company)."

7. "**THAT** conditional upon the passing of resolutions nos. 5 and 6 as set out in the notice convening the meeting of which this resolution forms part, the general mandate referred to in resolution no. 6 as set out in the notice convening the meeting of which this resolution forms part be and is hereby extended by the addition to the aggregate number of Shares which may be allotted and issued or agreed conditionally or unconditionally to be allotted and issued (including Treasury Shares, if any, sold or transferred or agreed conditionally or unconditionally to be sold or transferred) by the directors of the Company pursuant to such general mandate of an amount representing the aggregate number of Shares repurchased by the Company since the granting of the said general mandate pursuant to the exercise by the directors of the Company of the powers of the Company to purchase such shares provided that such amount shall not exceed 10% of the total number of Shares (excluding Treasury Shares, if any) in issue on the date of passing of this resolution."

By Order of the Board
Meilleure Health International Industry Group Limited
Zhou Wen Chuan
Executive Director and Chief Executive Officer

Hong Kong, 28 April 2026

Notes:

1. A member entitled to attend and vote at the meeting is entitled to appoint another person as his proxy to attend and vote on his behalf. A member who is the holder of two or more shares may appoint more than one proxy to attend on the same occasion. A proxy need not be a member of the Company. If more than one proxy is appointed, the appointment shall specify the number and class of shares in respect of which each such proxy is so appointed.

2. To be valid, the instrument appointing a proxy and the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power or authority, must be deposited at the Company's branch share registrars in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 48 hours before the time appointed for holding the meeting or any adjourned meeting (as the case may be).

3. The register of members of the Company will be closed from Monday, 22 June 2026 to Friday, 26 June 2026 (both days inclusive) for the purpose of determining entitlement of the shareholders of the Company to attend and vote at the aforesaid meeting, during which period no transfer of the Shares will be effected. In order to qualify for attending and voting at the aforesaid meeting, all transfers of the Shares accompanied by the relevant share certificates must be lodged with the Hong Kong share registrar of the Company, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration no later than 4: 30 p.m. on Thursday, 18 June 2026. The record date for the purpose of ascertaining Shareholders' right to attend and vote at the AGM will be 26 June 2026.

4. In order to determine the entitlement of the shareholders to receive the proposed final dividend, if approved, the register of members of the Company will be closed from Tuesday, 4 August 2026 to Wednesday, 5 August 2026, during which no transfer of the Shares will be registered. In order to be eligible to receive the proposed final dividend, all transfers of the Shares accompanied by the relevant share certificates and appropriate transfer forms must be lodged with the Company's share registrar in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4: 30 p.m. on Monday, 3 August 2026.